Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008

被引：70

作者：

Koulova, Anna ^{[1
]}

Tsui, Jennifer ^{[1
]}

Irwin, Kathleen ^{[1
]}

Van Damme, Pierre ^{[2
]}

Biellik, Robin ^{[3
]}

Aguado, Maria Teresa ^{[1
]}

机构：

[1] WHO, Initiat Vaccine Res, CH-1211 Geneva 27, Switzerland

[2] Univ Antwerp, Collaborating Ctr Vaccine Evaluat, WHO, Ctr Evaluat Vaccinat,Vaccine & Infect Dis Inst, Antwerp, Belgium

[3] PATH, F-01210 Ferney Voltaire, France

来源：

VACCINE | 2008年 / 26卷 / 51期

关键词：

Human papillomavirus; Cancer vaccines; Clinical practice guidelines;

D O I：

10.1016/j.vaccine.2008.08.067

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We analysed Country recommendations and funding plans finalized through January 2008 for the inclusion of quadrivalent and bivalent human papillomavirus (HPV) vaccines in national immunization programmes. Fifteen industrialized Countries have recommended HPV vaccine use based on careful review of scientific evidence and cost-effectiveness.There was a strong consensus among the guidelines regarding assessment of vaccine safety and efficacy, selection of primary target Populations for vaccination. vaccine delivery strategies, and the need for vaccinated females to seek cervical cancer screening. The analysis informs ongoing discussions in several countries considering HPV vaccines for national immunization programmes and discussions at the World Health Organization about global recommendations for HPV vaccine use for national immunization programmes.

引用

页码：6529 / 6541

页数：13

共 26 条

[1]

[Anonymous], HUMAN PAPILLOMAVIRUS

[2] Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women [J].

Block, Stan L. ;

Nolan, Terry ;

Sattler, Carlos ;

Barr, Eliav ;

Giacoletti, Katherine E. D. ;

Marchant, Colin D. ;

Castellsague, Xavier ;

Rusche, Steven A. ;

Lukac, Suzanne ;

Bryan, Janine T. ;

Cavanaugh, Paul F., Jr. ;

Reisinger, Keith S. .

PEDIATRICS, 2006, 118 (05) :2135-2145

[3] HPV and cervical cancer:: screening or vaccination? [J].

Bosch, F. X. ;

Castellsague, X. ;

de Sanjose, S. .

BRITISH JOURNAL OF CANCER, 2008, 98 (01) :15-21

[4]

CASTELLSAGUE X, 2007, VACCINE S3, V25

[5] Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice [J].

Coulfield, Michael J. ;

Shi, Li ;

Wang, Su ;

Wang, Bei ;

Tobery, Timothy W. ;

Mach, Henryck ;

Ahl, Patrick L. ;

Cannon, Jayme L. ;

Cook, James C. ;

Heinrichs, Jon H. ;

Sitrin, Robert D. .

HUMAN VACCINES, 2007, 3 (04) :139-145

[6]

*EMEA, EUR PUBL ASS REP EPA

[7]

*EUR CERV CANC ASS, CERV CANC EUR

[8]

FitzSimons David, 2007, Vaccine, V25, P8651, DOI 10.1016/j.vaccine.2007.10.005

[9] Issues in planning cervical cancer screening in the era of HPV vaccination [J].

Franco, Eduardo L. ;

Cuzick, Jack ;

Hildesheim, Allan ;

de Sanjose, Silvia .

VACCINE, 2006, 24 :171-177

[10] Exploring the knowledge, attitudes, beliefs, and communication preferences of the general public regarding HPV: Findings from CDC focus group research and implications for practice [J].

Friedman, Allison L. ;

Shepeard, Hilda .

HEALTH EDUCATION & BEHAVIOR, 2007, 34 (03) :471-485

← 1 2 3 →